Regulatory News
The United States has no pre-market approval for cosmetics. That single fact shapes every conversation about exporting powders there, and it is also the reason the 2022 Modernization of Cosmetics Regulation Act (MoCRA) matters so much: it did not introduce approval, but it replaced a largely voluntary system with registered facilities, listed products and substantiated safety files.
Under the FD&C Act, a cosmetic is an article intended to be applied to the human body for cleansing, beautifying or altering appearance. A mineral powder sold as a cosmetic ingredient is regulated through the finished product it goes into, not through a pre-market licence of its own.
Two colour additives are the classic exception. If a powder is also a colour additive — titanium dioxide is the usual example — its use is subject to the colour additive provisions, which are stricter than the general cosmetic provisions. Confirm the intended use with the brand before assuming the lighter pathway applies.
MoCRA was signed in December 2022 and created four obligations that touch ingredient suppliers indirectly but unmistakably:
Note the direction of the obligations: they sit on the brand and the facility, not on the mineral supplier. What a supplier controls is whether the brand can satisfy them, and that is where documentation becomes commercial.
Talc has been the subject of sustained attention because of asbestos contamination in historical supply chains. FDA has been developing a standardised testing method for asbestos in talc-containing cosmetic products. For any talc grade destined for the US, assume the buyer will require:
The same logic is spreading to other mineral powders even where no specific rule exists. Buyers of mica, kaolin and silica increasingly ask for the same declarations as a matter of procurement policy.
Product listing requires ingredients to be declared. Where a supplier's commercial name does not map cleanly onto an INCI name, the brand either lists something wrong or spends weeks resolving it. Supply the INCI name for every component, including treatment agents, alongside the trade name.
This is also where "proprietary treatment" language backfires. A brand cannot list an undisclosed treatment agent, so an unnamed treatment becomes a listing blocker.
| Item | Why it is asked for |
|---|---|
| INCI names for all components | Product listing cannot be completed without them |
| Safety Data Sheet (GHS) | Hazard communication and internal safety review |
| Heavy metal and microbiological data | Feeds the safety substantiation file |
| Non-asbestos declaration (talc) | Named method, batch-linked |
| Batch traceability | Required for adverse event investigation |
MoCRA did not make the US market harder to enter; it made it harder to enter with thin documentation. A supplier who can hand over INCI-mapped composition, batch-level impurity data and a method-specific asbestos declaration for talc is removing work from the brand's compliance team. In a market with no pre-market approval, that documentation is the barrier to entry.
US requirements under MoCRA continue to be implemented through guidance and rulemaking. Verify current obligations with the brand or a US regulatory consultant before shipping; the framework above is stable, the specific deadlines are not.
Related products
We reply within one business day with shipping arrangements and technical documents. Samples are free of charge; freight is collect or credited against your next order.